Medical Policy: 02.04.28 
Original Effective Date: March 2010 
Reviewed: March 2016 
Revised: March 2016 


Benefit Application:

Benefit determinations are based on the applicable contract language in effect at the time the services were rendered. Exclusions, limitations or exceptions may apply. Benefits may vary based on contract, and individual member benefits must be verified. Wellmark determines medical necessity only if the benefit exists and no contract exclusions are applicable. This medical policy may not apply to FEP. Benefits are determined by the Federal Employee Program.

This Medical Policy document describes the status of medical technology at the time the document was developed. Since that time, new technology may have emerged or new medical literature may have been published. This Medical Policy will be reviewed regularly and be updated as scientific and medical literature becomes available.


Description:

Gene expression profiling (GEP) assays have been developed and reported for use as prognostic markers in stage 2 or stage 3 colon cancer. These assays are intended to help identify those individuals who are at high risk for recurrent disease and would be candidates for adjuvant tchemoherapy. The number of gene sequences explored vary depending upon the assay used and may range from as few as 5 to as many as several hundred. 

 

Colorectal cancer is classified as stage 2 when it has spread outside the colon and/or rectum to nearby tissue but is not detectable in the lymph nodes and has not metastasized to distant sites. The primary treatment for stage 2 colon cancer is surgical resection of the primary cancer and colonic anastomosis. 

 

The survival rate following surgery is 75% to 80% at 5 years. Recurrence following surgery is a major concern and is frequently the ultimate cause of death. Patients most likely to benefit from chemotherapy are difficult to identify by standard clinical and pathologic risk factors. Genomic tests are intended to be used as an aid for identifying stage 2 patients most likely to experience recurrence after surgery and most likely to benefit from additional treatment.

 

For patients with stage 3 colon cancer, current guidelines from the National Comprehensive Cancer Network recommend “6 months of adjuvant chemotherapy after primary surgical treatment.” However, some have questioned the benefit of adjuvant chemotherapy in subsets of patients with stage 3 disease (e.g., stage 3A) whose predicted survival may actually exceed that of some stage 2 patients (e.g., stage 2C). 


Several assays are available in the United States: ColonPRS®, Signal Genetics, New York, NY; Coloprint®, Agendia NV, Amsterdam, Netherlands; Genefx Colon®, Precision Therapeutics, Pittsburgh, PA; OncoDefender-CRC (colon and rectal cancer), Everist Genomics, Ann Arbor, MI; and Oncotype DX® Colon Cancer Test, Genomic Health, Inc., Redwood City, CA. Independent validation studies ranging in size from 33 to 1436 patients have been reported on these assays.

 

ColonPRS®:

In 2010 Van Laar reported on a 163-gene expression test using data from 232 colon cancer patients across all stages of disease. ColonPRS® is being marketed as a research use only test and has specific warnings against clinical use.

 

Coloprint®

Salazar and colleagues in 2010 described the development of an 18-gene expression test (the ColoPrint® test).  The test is reportedly able to stratisfy stage II colon cancers into low or high risk. This would determine if adjuvant chemotherapy is necessary.  A High Risk result means that a patient with stage II colon cancer has a 20% risk of relapse within 3 years and a 22% risk of relapse within 5 years3 without adjuvant  treatment.  Validation studies have been published only in abstract form at this time.

 

Genefx Colon®

In 2011, Kennedy et al. reported on the development of a 634-probe set signature.. Cross-validation studies were used to select an optimal transcript signature for prognostic classification.The authors noted a further retrospective validation of the test in a large cohort of stage II colon cancer samples collected as part of a clinical trial is planned.

 

OncoDefender

The test is performed by Everist Genomics. It is a 5-gene test reportedly able to accurately predict the risk of recurrence of cancer in patients previously treated with surgical resection(i.e. removal) of a Stage I or Stage II colon cancer tumor or a Stage 1 rectal cancer tumor. However, isolated performance of the test in patients with stage II colon cancer was not reported, and several high-risk findings (bowel obstruction/perforation, and lymphovascular invasion) demonstrated higher hazard ratios than observed using the molecular signature. The study (Lenehan 2012) alluded to but did not directly address clinical utility.

 

Oncotype DX®

O’Connell et al. in a 2010 described the development of a 12-gene expression test (the Oncotype DX® colon cancer test).. Gene expression was quantitated from microdissected fixed paraffin-embedded primary colon cancer tissue. The test was later reduced the genes to a 7-gene prognostic signature and a separate 6-gene predictive signature. Five reference genes are also included in the assay.

 

Clinical utility

No studies of a GEP for determining prognosis of patients with stage II colon cancer have been published demonstrating the effect of testing on overall reclassification of patients when compared to existing methods of risk analysis. There is no published information on the impact from use of GEP results on patient outcomes. In the absence of information showing a direct effect on outcomes or establishing a strong chain of evidence that testing would be expected to have a positive net effect on outcomes, clinical utility remains unclear.

 

A Technical Brief, published by the Agency for Healthcare Research and Quality in December 2012, reviewed the clinical evidence for GEP for predicting outcomes, including benefit from adjuvant chemotherapy, in patients with stage 2 colon cancer. The 4 assays reviewed earlier that are commercially available for clinical use were included in the brief. No prospective studies were identified that assessed change in net health outcome with use of a GEP assay, and no studies were identified that used a net reclassification analysis and subsequently evaluated the impact of the reclassification on net health outcome. Additionally, evidence was limited on the reproducibility of test findings, indications for GEP testing in stage 2 patients, and whether results of GEP assays can stratify patients into groups defined by clinically meaningful differences in recurrence risk.

 

Summary

The available evidence indicates that gene expression profile (GEP) tests for colon cancer can improve risk prediction, particularly the risk of recurrence in patients with Stage II colon cancer. However, evidence to date is insufficient to permit conclusions on how GEP classification compares with other approaches for identifying recurrence risk in stage II patients or on how GEP classification impacts patient outcomes (clinical utility). There is even less evidence to permit conclusions on how GEP classification compares with other approaches for management of other stages of colon cancer. Therefore, the use of GEP assays to predict the likelihood of disease recurrence for patients with colon cancer, is considered investigational.

   

Regulatory Status

To date, no gene expression test for evaluation of prognosis in stage II colon cancer has been cleared for marketing by the United States Food and Drug Administration (FDA). These tests are offered as laboratory-developed assays in clinical laboratory improvement amendment (CLIA)-licensed laboratories operated by each company and currently do not require FDA premarket review as a result of enforcement discretion.

 

Practice Guidelines and Position Statements

National Comprehensive Cancer Network (NCCN), Colon Cancer, Version 2.2016

Multigene Assays

Several multigene assays have been developed in hopes of providing prognostic and predictive information to aid in decisions regarding adjuvant therapy in patients with stage 2 or 3 colon cancer.

  • Oncotype DX colon cancer assay (Genomic Health, inc) quantifies the expression of 7 recurrence risk genes and 5 reference genes as prognostic classifier of low, intermediate or high likelihood of recurrence. 
  • ColoPrint (Agendia) quantifies the expression of 18 genes as a prognostic classifier of low versus high recurrence risk. 
  • ColDx (Almac) is a microarray based multigene assay that uses 634 probes to identify patients with stage 2 colon cancer at high risk of recurrence.

In summary, the information from these tests can further inform the risk of recurrence over other risk factors, but the panel questions the value added. Furthermore, there is no evidence of predictive value in terms of the potential benefit of chemotherapy to any of the available multigene assays. The panel believes that there are insufficient data to recommend the use of multigene assays to determine adjuvant therapy.


Prior Approval:

 

Not applicable


Policy:

Gene expression profile (GEP) assays as a technique for managing colon cancer is  considered investigational for all indications, including but not limited to its use for predicting the likelihood of disease recurrence in individuals with colon cancer following surgery.

 

Gene expression profile (GEP) assays, including but not limited to the following are considered investigational:

  • Oncotype DX colon cancer assay
  • ColonPRS
  • OncoDefender
  • Genefx colon
  • Coloprint

The available evidence indicates that gene expression profile tests in patients who have stage 2 or stage 3 colon cancer includes development and validation studies. Relevant outcomes are disease-specific survival, test accuracy, test validity, and change in disease status. The available evidence indicates that GEP tests for colon cancer can improve risk prediction, particularly the risk of recurrence in patients with stage 2 or 3 colon cancer. However, the evidence to date is insufficient to permit conclusions on how gene expression profile (GEP) classification compares with other approaches for identifying risk in stage 2 patients or on how GEP classification impacts patient outcomes (clinical utility). There is even less evidence to permit conclusions on how GEP classification compares with other approaches for management of other stages of colon cancer. The evidence is insufficient to determine the effects of the technology on health outcomes.  Therefore, use of these gene expression profile (GEP) assays, including predicting the likelihood of disease recurrence for patients with colon cancer, is considered investigational.



Procedure Codes and Billing Guidelines:

  • To report provider services, use appropriate CPT* codes, Modifiers, Alpha Numeric (HCPCS level 2) codes, Revenue codes, and/or diagnosis codes.
  • 81525 Oncology (colon), mRNA, gene expression profiling by real-time RT-PCR of 12 genes (7 content and 5 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a recurrence score
  • 84999 Unlisted chemistry procedure
  • 88299 Unlisted cytogenetic study
  • 81599 Unlisted multianalyt assay with algorithmic analysis

Selected References:

  • O'Connell MJ, Lavery I, Yothers G et al. Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. J Clin Oncol 2010; 28(25):3937-44.
  • Gray RG, Quirke P, Handley K et al. Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer. J Clin Oncol 2011; 29(35):4611-19.
  • Lenehan PF, Boardman LA, Riegert- Johnson D et al. Generation and external validation of a tumor-derived 5-gene prognostic signature for recurrence of lymph node-negative, invasive colorectal carcinoma. Cancer. 2012 May 17. doi: 10.1002/cncr.27628. [Epub ahead of print].
  • Kennedy RD, Bylesjo M, Kerr P et al. Development and independent validation of a prognostic assay for stage II colon cancer using formalin-fixed paraffin-embedded tissue. J Clin Oncol 2011; 29(35):4620-26.
  • Salazar R, Roepman P, Capella G et al. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J Clin Oncol 2011; 29(1):17-24.
  • Van Laar R. An online gene expression assay for determining adjuvant therapy eligibility in patients with stage 2 or 3 colon cancer. Br J Cancer 2010; 103(12):1852-7.
  • Hong Y, Downey T, Eu KW et al. A "metastasis-prone" signature for early-stage mismatch-repair proficient sporadic colorectal cancer patients and its implications for possible therapeutics. Clin Exp Metastasis 2010;27(2):83-90.
  • Kelley RK, Van Bebber SL, Phillips KA et al. Personalized medicine and oncology practice guidelines: a case study of contemporary biomarkers in colorectal cancer. J Natl Compr Canc Netw. 2011;9(1):13-25.
  • Ross JS. Biomarker-based selection of therapy for colorectal cancer. Biomarkers in Medicine. 2011;5(3):319-32.
  • Webber EM, Lin JS, Evelyn PW. Oncotype DX tumor gene expression profiling in stage II colon cancer. Application: prognostic, risk prediction. PLoS Curr. 2010.
  • ECRI External SiteMultigene Expression Assay (Oncotype DX) for Predicting Recurrence of Colon Cancer. Plymouth Meeting (PA): ECRI Institute; 2011 Nov 16. [ECRI hotline response].
  • Maak M, Simon I et al. Independent validation of a prognostic genomic signature (ColoPrint) for patients with statge II colon cancer. Ann Surgery 2013 257(6)1053-8.
  • National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology External SiteColon Cancer V.3.2013.
  • ECRI Institute. Oncotype DX multigene expression assay for predicting recurrence of colon cancer. ECRI Institute; 2013 Jul 2 [ECRI Procuct Brief]. Retrieved 7/11/13.
  • National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology External Site
  • ECRI External SiteProduct Brief. Oncotype DX Multigene Expression Assay (Genomic Health, Inc) for Predicting Recurrence of Colon Cancer, June 2014.
  • Srivastava G, Renfro LA, et. al. Prospective Multicenter Study of the Impact of Oncotype DX Colon Cancer Assay Results on Treatment Recommendations in Stage II Colon Cancer Patients, Oncologist 2014 May;19(5):492-7
  • UpToDate External SiteAdjuvant Chemotherapy for Resected Stage II Colon Cancer, Hanna K. Sanoff, M.D., MPH. Topic last updated March 19, 2015.
  • UpToDate External SiteAdjuvant Therapy for Resected Stage III (node-positive) Colon Cancer. Jeffrey W. Clark, M.D., Hanna K. Sanoff, M.D., MPH. Topic last updated February 20, 2015.
  • UpToDate External SiteOverview of Gene Expression Profiling, Proteomics and MicroRNA Profiling in Clinical Oncology, Patrick C ma, M.D., MSc. Topic last updated March 18, 2015.
  • Smith JJ, Deane NG, Wu F, et al. Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer. Gastroenterology. Mar 2010;138(3):958-968. PMID 19914252
  • Marisa L, de Reynies A, Duval A, et al. Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value. PLoS Med. 2013;10(5):e1001453. PMID 23700391
  • Herrera M, Islam AB, Herrera A, et al. Functional heterogeneity of cancer-associated fibroblasts from human colon tumors shows specific prognostic gene expression signature. Clin Cancer Res. Nov 1 2013;19(21):5914-5926. PMID 24052018
  • Zhang JX, Song W, Chen ZH, et al. Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis. Lancet Oncol. Dec 2013;14(13):1295-1306. PMID 24239208
  • Maak M, Simon I, Nitsche U, et al. Independent validation of a prognostic genomic signature (ColoPrint) for patients with stage II colon cancer. Ann Surg. Jun 2013;257(6):1053-1058. PMID 23295318
  • Kopetz S, Tabernero J, Rosenberg R, et al. Genomic classifier ColoPrint predicts recurrence in stage II colorectal cancer patients more accurately than clinical factors. Oncologist. Feb 2015;20(2):127-133. PMID 25561511
  • Lenehan PF, Boardman LA, Riegert-Johnson D, et al. Generation and external validation of a tumor-derived 5-gene prognostic signature for recurrence of lymph node-negative, invasive colorectal carcinoma. Cancer. May 17 2012;118(21):5234-5244. PMID 22605513
  • Yothers G, O'Connell MJ, Lee M, et al. Validation of the 12-gene colon cancer recurrence score in NSABP C-07 as a predictor of recurrence in patients with stage II and III colon cancer treated with fluorouracil and leucovorin (FU/LV) and FU/LV plus oxaliplatin. J Clin Oncol. Dec 20 2013;31(36):4512-4519. PMID 24220557
  • Reimers MS, Kuppen PJ, Lee M, et al. Validation of the 12-gene colon cancer recurrence score as a predictor of recurrence risk in stage II and III rectal cancer patients. J Natl Cancer Inst. Nov 2014;106(11). PMID 25261968
  • Cartwright T, Chao C, Lee M, et al. Effect of the 12-gene colon cancer assay results on adjuvant treatment recommendations in patients with stage II colon cancer. Curr Med Res Opin. Feb 2014;30(2):321-328. PMID 24127781
  • Srivastava G, Renfro LA, Behrens RJ, et al. Prospective multicenter study of the impact of oncotype DX colon cancer assay results on treatment recommendations in stage II colon cancer patients. Oncologist. May 2014;19(5):492-497. PMID 24710310
  • Black E, Falzon L, Aronson N. Gene Expression Profiling for Predicting Outcomes in Stage II Colon Cancer External SiteTechnical Brief. No. 13. (Prepared by the Blue Cross and Blue Shield Association Technology Evaluation Center Evidence-based Practice Center under Contract No. 290-2007-0058-I.) Rockville, MD: Agency for Healthcare Research and Quality. December 2012. Accessed June 12, 2015.
  • Webber Elizabeth, Lin J, Whitlock E. Oncotype DX tumor gene expression profiling in stage II colon cancer. Application: Prognostic, risk prediction. Version 1 PLoS Curr 2010 September 2; 2 RRN1177.
  • ECRI External SiteGenetic Test Product Brief. Oncotype DX Multigene Expression Assay (Genomic Health, Inc.) for Predicting Recurrence of Colon Cancer. August 2015.
  • Reimers MS, Zeestraten EC,Kuppen PJ, et.al. Biomarkers in precision therapy in colorectal cancer. Gastroentrol Rep (Oxf) 2013 Nov:1(3):166-83
  • Goel G. Evolving role of gene expression signatures as biomarkers in early-stage colon cancer. J Gastrointest Cancer. 2014 Dec:45(4):399-404. PMID 24989938

Policy History:

  • March 2016 - Annual Review, Policy Revised
  • April 2015 - Annual Review, Policy Revised
  • October 2014 - Interim review, Policy Revise
  • May 2014 - Annual Review, Policy Revised
  • July 2013 - Annual Review, Policy Renewed
  • August 2012 - Annual Review, Policy Revised
  • August 2011 - Annual Review, Policy Renewed

Wellmark medical policies address the complex issue of technology assessment of new and emerging treatments, devices, drugs, etc.   They are developed to assist in administering plan benefits and constitute neither offers of coverage nor medical advice. Wellmark medical policies contain only a partial, general description of plan or program benefits and do not constitute a contract. Wellmark does not provide health care services and, therefore, cannot guarantee any results or outcomes. Participating providers are independent contractors in private practice and are neither employees nor agents of Wellmark or its affiliates. Treating providers are solely responsible for medical advice and treatment of members. Our medical policies may be updated and therefore are subject to change without notice.

*Current Procedural Terminology © 2012 American Medical Association. All Rights Reserved.